Branning Todd P. 4
4 · Amneal Pharmaceuticals, Inc. · Filed Mar 2, 2020
Insider Transaction Report
Form 4
Branning Todd P.
SVP, Chief Financial Officer
Transactions
- Award
Restricted Stock Units
2020-02-27+83,113→ 83,113 total→ Class A Common Stock (83,113 underlying) - Award
Performance-Based Restricted Stock Units
2020-02-27+166,226→ 166,226 total→ Class A Common Stock (166,226 underlying)
Footnotes (5)
- [F1]Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock.
- [F2]The restricted stock units vest in four equal annual installments beginning on February 27, 2021.
- [F3]Each performance-based restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock.
- [F4]Represents the maximum number of shares issuable under the performance-based restricted stock units.
- [F5]25% of the performance-based restricted stock units are earned and eligible to vest upon the Issuer's Class A Common Stock achieving an average closing price per share of $8 or higher for 60 consecutive calendar days during the three-year performance period. An additional 12.5% of the performance-based restricted stock units are earned and eligible to vest upon the Issuer's Class A Common Stock achieving an average closing price per share of $10, $12, $14, $16, $18 and $20, respectively, for 60 consecutive calendar days during the three-year performance period. For average 60-day closing stock prices between $12 and $20 per share, the number of performance-based restricted stock units that become earned will be determined using straight line interpolation. Any earned performance-based restricted stock units vest in full on February 28, 2023, the last day of the performance period.